Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin J Parks

Showing results (1-10 of 96) with videos related to

Pageof 10
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 9, 2004
Adenovirus protein IX: a new look at an old proteinRobin J Parks
Current Gene Therapy|July 12, 2002
Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapyAndrea Amalfitano, Robin J Parks
Journal of Virology|April 5, 2019
Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Suppresses Human Adenovirus Gene Expression and ReplicationBratati Saha, Robin J Parks
Human Gene Therapy|November 19, 2010
Rational design of murine secreted alkaline phosphatase for enhanced performance as a reporter gene in mouse gene therapy preclinical studiesCarin Christou, Robin J Parks
Microorganisms|August 27, 2020
Recent Advances in Novel Antiviral Therapies against Human AdenovirusBratati Saha, Robin J Parks
Plos One|July 13, 2017
Human adenovirus type 5 vectors deleted of early region 1 (E1) undergo limited expression of early replicative E2 proteins and DNA replication in non-permissive cellsBratati Saha, Robin J Parks
Proceedings of the National Academy of Sciences of the United States of America|September 8, 2018
Building immune tolerance through DNA vaccinationRobin J Parks, Emanuela Gussoni
Virology|October 9, 2020
Identification of human adenovirus replication inhibitors from a library of small molecules targeting cellular epigenetic regulatorsBratati Saha, Robin J Parks
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 25, 2003
Oncolytic adenovirus: getting there is half the battleP Joel Ross, Robin J Parks
Pharmaceutics|June 28, 2023
Expanding the Availability of Onasemnogene Abeparvovec to Older Patients: The Evolving Treatment Landscape for Spinal Muscular AtrophyCharlotte A René, Robin J Parks
Pageof 10

Showing results (1-10 of 96) with videos related to

Sort By:
Pageof 10
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 9, 2004
Adenovirus protein IX: a new look at an old proteinRobin J Parks
Current Gene Therapy|July 12, 2002
Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapyAndrea Amalfitano, Robin J Parks
Journal of Virology|April 5, 2019
Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Suppresses Human Adenovirus Gene Expression and ReplicationBratati Saha, Robin J Parks
Human Gene Therapy|November 19, 2010
Rational design of murine secreted alkaline phosphatase for enhanced performance as a reporter gene in mouse gene therapy preclinical studiesCarin Christou, Robin J Parks
Microorganisms|August 27, 2020
Recent Advances in Novel Antiviral Therapies against Human AdenovirusBratati Saha, Robin J Parks
Plos One|July 13, 2017
Human adenovirus type 5 vectors deleted of early region 1 (E1) undergo limited expression of early replicative E2 proteins and DNA replication in non-permissive cellsBratati Saha, Robin J Parks
Proceedings of the National Academy of Sciences of the United States of America|September 8, 2018
Building immune tolerance through DNA vaccinationRobin J Parks, Emanuela Gussoni
Virology|October 9, 2020
Identification of human adenovirus replication inhibitors from a library of small molecules targeting cellular epigenetic regulatorsBratati Saha, Robin J Parks
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 25, 2003
Oncolytic adenovirus: getting there is half the battleP Joel Ross, Robin J Parks
Pharmaceutics|June 28, 2023
Expanding the Availability of Onasemnogene Abeparvovec to Older Patients: The Evolving Treatment Landscape for Spinal Muscular AtrophyCharlotte A René, Robin J Parks
Pageof 10